JP2021073250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021073250A5 JP2021073250A5 JP2021009651A JP2021009651A JP2021073250A5 JP 2021073250 A5 JP2021073250 A5 JP 2021073250A5 JP 2021009651 A JP2021009651 A JP 2021009651A JP 2021009651 A JP2021009651 A JP 2021009651A JP 2021073250 A5 JP2021073250 A5 JP 2021073250A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- disorder
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636252P | 2012-04-20 | 2012-04-20 | |
| US61/636,252 | 2012-04-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018237492A Division JP2019059781A (ja) | 2012-04-20 | 2018-12-19 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021073250A JP2021073250A (ja) | 2021-05-13 |
| JP2021073250A5 true JP2021073250A5 (https=) | 2021-07-26 |
Family
ID=48325893
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507213A Active JP6165843B2 (ja) | 2012-04-20 | 2013-04-19 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| JP2017091568A Active JP6457010B2 (ja) | 2012-04-20 | 2017-05-02 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| JP2018237492A Withdrawn JP2019059781A (ja) | 2012-04-20 | 2018-12-19 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| JP2021009651A Pending JP2021073250A (ja) | 2012-04-20 | 2021-01-25 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507213A Active JP6165843B2 (ja) | 2012-04-20 | 2013-04-19 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| JP2017091568A Active JP6457010B2 (ja) | 2012-04-20 | 2017-05-02 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| JP2018237492A Withdrawn JP2019059781A (ja) | 2012-04-20 | 2018-12-19 | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9546194B2 (https=) |
| EP (2) | EP2838907B1 (https=) |
| JP (4) | JP6165843B2 (https=) |
| KR (3) | KR101963312B1 (https=) |
| AU (3) | AU2013249111B2 (https=) |
| CA (1) | CA2870671C (https=) |
| DK (1) | DK2838907T3 (https=) |
| ES (1) | ES2736310T3 (https=) |
| HR (1) | HRP20191348T1 (https=) |
| HU (1) | HUE044769T2 (https=) |
| MX (2) | MX367255B (https=) |
| PL (1) | PL2838907T3 (https=) |
| PT (1) | PT2838907T (https=) |
| TR (1) | TR201911039T4 (https=) |
| WO (1) | WO2013158970A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2736310T3 (es) * | 2012-04-20 | 2019-12-27 | Ohr Pharmaceutical Inc | Aminoesteroides para el tratamiento de una enfermedad asociada a PTP1B |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| MA50094A (fr) * | 2017-09-08 | 2020-07-15 | Enterin Inc | Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol |
| CN107802626B (zh) * | 2017-10-11 | 2020-01-21 | 南昌大学 | 降血糖组合物及其制备方法、用途 |
| CN111801102B (zh) * | 2017-11-06 | 2024-05-28 | 冷泉港实验室 | 用于形成含铜络合物的方法和组合物及其用途 |
| KR20200146038A (ko) * | 2018-03-27 | 2020-12-31 | 엔테린, 인코포레이티드 | 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물 |
| AU2019308311B2 (en) * | 2018-07-20 | 2024-12-05 | Cold Spring Harbor Laboratory | (pyridinylmethyl)butanediamine derivatives that chelate copper |
| WO2021025974A1 (en) * | 2019-08-02 | 2021-02-11 | Enterin, Inc. | Human squalamine derivatives, related compositions comprising the same, and methods of using the same |
| EP4007764B1 (en) * | 2019-08-02 | 2026-01-21 | Enterin, Inc. | Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same |
| WO2023230593A1 (en) | 2022-05-27 | 2023-11-30 | Cold Spring Harbor Laboratory | Ptp1b inhibitors for treating lung injury |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2403683A (en) * | 1942-04-25 | 1946-07-09 | Relchstein Tadeus | Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same |
| US3636210A (en) * | 1968-02-02 | 1972-01-18 | Merck & Co Inc | Cholanic acid and cholenic acid compositions and method of treatment |
| IT1255450B (it) * | 1992-06-30 | 1995-10-31 | Montefarmaco Spa | Uso di acidi biliari come agenti antivirali |
| WO1994019366A1 (en) * | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| DE69412596T2 (de) * | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| ATE259375T1 (de) * | 1995-06-07 | 2004-02-15 | Genaera Corp | Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| EP1214060A2 (en) | 1999-09-10 | 2002-06-19 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| AU6985300A (en) | 1999-09-10 | 2001-04-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| JP2003509429A (ja) | 1999-09-10 | 2003-03-11 | ノボ ノルディスク アクティーゼルスカブ | タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター |
| WO2001042273A2 (en) | 1999-12-09 | 2001-06-14 | Genaera Corporation | Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| AU2003292939A1 (en) * | 2002-12-24 | 2004-07-22 | The University Of British Columbia | Angiogenic compounds and uses thereof |
| JP2006165843A (ja) * | 2004-12-06 | 2006-06-22 | Matsushita Electric Ind Co Ltd | 画像処理装置 |
| US20080058300A1 (en) * | 2006-04-21 | 2008-03-06 | Mclane Michael | Induction of weight loss and the selective inhibition of PTP1B |
| JP2010538072A (ja) * | 2007-09-06 | 2010-12-09 | ジェナエラ コーポレイション | 糖尿病を治療する方法 |
| KR101260221B1 (ko) * | 2011-12-01 | 2013-05-06 | 주식회사 엘지화학 | 마스크 |
| ES2736310T3 (es) * | 2012-04-20 | 2019-12-27 | Ohr Pharmaceutical Inc | Aminoesteroides para el tratamiento de una enfermedad asociada a PTP1B |
-
2013
- 2013-04-19 ES ES13721176T patent/ES2736310T3/es active Active
- 2013-04-19 HR HRP20191348TT patent/HRP20191348T1/hr unknown
- 2013-04-19 KR KR1020167019758A patent/KR101963312B1/ko not_active Expired - Fee Related
- 2013-04-19 PT PT13721176T patent/PT2838907T/pt unknown
- 2013-04-19 JP JP2015507213A patent/JP6165843B2/ja active Active
- 2013-04-19 MX MX2014012619A patent/MX367255B/es active IP Right Grant
- 2013-04-19 HU HUE13721176 patent/HUE044769T2/hu unknown
- 2013-04-19 AU AU2013249111A patent/AU2013249111B2/en active Active
- 2013-04-19 DK DK13721176.9T patent/DK2838907T3/da active
- 2013-04-19 US US14/394,789 patent/US9546194B2/en active Active
- 2013-04-19 KR KR1020197008179A patent/KR102057812B1/ko active Active
- 2013-04-19 TR TR2019/11039T patent/TR201911039T4/tr unknown
- 2013-04-19 KR KR1020147031485A patent/KR20150003798A/ko not_active Ceased
- 2013-04-19 PL PL13721176T patent/PL2838907T3/pl unknown
- 2013-04-19 EP EP13721176.9A patent/EP2838907B1/en active Active
- 2013-04-19 CA CA2870671A patent/CA2870671C/en active Active
- 2013-04-19 WO PCT/US2013/037330 patent/WO2013158970A2/en not_active Ceased
- 2013-04-19 EP EP19175554.5A patent/EP3556765B1/en active Active
-
2014
- 2014-10-17 MX MX2019009539A patent/MX2019009539A/es unknown
-
2016
- 2016-10-06 US US15/286,646 patent/US20170129914A1/en not_active Abandoned
-
2017
- 2017-05-02 JP JP2017091568A patent/JP6457010B2/ja active Active
-
2018
- 2018-10-31 AU AU2018256561A patent/AU2018256561B2/en active Active
- 2018-12-19 JP JP2018237492A patent/JP2019059781A/ja not_active Withdrawn
-
2019
- 2019-03-12 US US16/299,872 patent/US10556923B2/en active Active
-
2020
- 2020-01-30 US US16/777,253 patent/US11434257B2/en active Active
- 2020-06-05 AU AU2020203736A patent/AU2020203736B2/en active Active
-
2021
- 2021-01-25 JP JP2021009651A patent/JP2021073250A/ja active Pending
-
2022
- 2022-07-29 US US17/877,498 patent/US20230203088A1/en not_active Abandoned
-
2024
- 2024-01-29 US US18/425,572 patent/US20250002525A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021073250A5 (https=) | ||
| JP2019059781A5 (https=) | ||
| JP2020169171A5 (https=) | ||
| JP2008514611A5 (https=) | ||
| JP2006502283A5 (https=) | ||
| JP2005112864A5 (https=) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2020507589A5 (https=) | ||
| JP2002541233A5 (https=) | ||
| JP2011500562A5 (https=) | ||
| JP2004536811A5 (https=) | ||
| JP2008513498A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JPWO2019155399A5 (https=) | ||
| JPWO2019195124A5 (https=) | ||
| JPWO2023099623A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| CA2463102A1 (en) | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | |
| JP2007502295A5 (https=) | ||
| JP2007501809A5 (https=) | ||
| JP2015514781A5 (https=) | ||
| JP2007502817A5 (https=) | ||
| JP2007506792A5 (https=) | ||
| JP2005517665A5 (https=) | ||
| JP2010507590A5 (https=) |